中国药物经济学2025，Vol.20Issue(1)：5-11,7.DOI:10.12010/j.issn.1673-5846.2025.01.001
莫诺拉韦对比最佳支持疗法治疗成人新型冠状病毒肺炎患者的成本-效果分析
Cost-effectiveness Analysis of Monolavir versus Optimal Supportive Therapy in Adult Patients with COVID-19
彭小宸 1符雨嫣 1程文迪 1孙辉 1王江娜 2王海银 1金春林 1Goswami Hardik3
作者信息
- 1. 上海市卫生和健康发展研究中心(上海市医学科学技术情报研究所),上海 201199
- 2. 江西中医药大学经济与管理学院,南昌 330004
- 3. BARDS Health Economic and Decision Sciences,Merck&Co,Inc,Rahway NJ,USA 07065
- 折叠
摘要
Abstract
Objective To evaluate the cost-effectiveness of Monolavir versus optimal supportive therapy in adult patients with novel coronavirus pneumonia(COVID-19).Methods From the perspective of the Chinese health system,a short-term decision tree model combined with a long-term Markov model was constructed to conduct cost-effectiveness analysis of Monolavir and optimal supportive therapy in adults with mild and moderate COVID-19 who are at high risk of progression to severe disease.At the same time,single factor sensitivity analysis and probability sensitivity analysis were carried out.Results The research results showed that compared to BSC,molnupiravir was cost-saving(-638.31 RMB)and resulted in a net gain of 0.171 2 QALYs,indicating that molnupiravir was a dominant option compared to BSC.Based on the PSA results,the probability of cost-effectiveness of molnupiravir compared to the BSC at a threshold of one-time per capita GDP is 98%.Through DSA,molnupiravir treatment effect of hospitalization reduction was identified to be the most influential parameter.The results of the scenario analysis revealed that molnupiravir has more benefits in older patients(0.307 7 QALYs).Conclusion Molnupiravir is cost-effective compared to using BSC for adult patients with mild to moderate novel coronavirus infection.关键词
新型冠状病毒肺炎/成本-效果分析/莫诺拉韦Key words
COVID-19/Cost-effectiveness analysis/Molnupiravir分类
医药卫生引用本文复制引用
彭小宸,符雨嫣,程文迪,孙辉,王江娜,王海银,金春林,Goswami Hardik..莫诺拉韦对比最佳支持疗法治疗成人新型冠状病毒肺炎患者的成本-效果分析[J].中国药物经济学,2025,20(1):5-11,7.
